Breakthrough Antiviral for Hantavirus Debuts in Europe

The European Commission has approved the dispatch of experimental antiviral favipiravir to France, Spain, and the Netherlands. Identified by the European Medicines Agency, favipiravir is the leading candidate for clinical trials or compassionate use in the treatment of hantavirus, which currently lacks a specific approved treatment.

Favipiravir, an experimental antiviral targeting hantavirus, is reaching France, Spain, and the Netherlands in its first deliveries, according to an announcement by the European Commission Thursday.

With no current approved treatment for hantavirus, the European Medicines Agency has highlighted favipiravir as a promising option for clinical trials or compassionate use.

The dispatch marks a critical step in Europe’s response to hantavirus, offering hope for a potential treatment breakthrough.